
Sai Parenterals Subsidiary to Acquire Majority Stake in Bion Therapeutics
Sai Parenterals Limited, through its wholly owned subsidiary SP Analytics Private Limited, has entered into a definitive agreement to acquire a majority stake in Bion Therapeutics India Private Limited (Bion). Bion, a Hyderabad-based branded formulations prescription business, will become a step-down subsidiary upon deal completion, expected by month-end. This all-cash transaction adds 16 established brands and approximately 250 field staff, significantly strengthening Sai Parenterals' presence in India's prescription market. Bion operates across 12 states with a strong presence in South, East, and Northeast India, focusing on niche therapeutic segments. The acquisition integrates Bion's doctor-led brands and distribution network with Sai Parenterals' manufacturing capabilities and R&D. The transaction will be funded through internal accruals, debt, and IPO proceeds.
Key Highlights
- Sai Parenterals to acquire majority stake in Bion Therapeutics via subsidiary SP Analytics.
- Acquisition adds 16 established brands and 250 field staff to strengthen prescription market presence.
- Transaction is an all-cash deal funded by internal accruals, debt, and IPO proceeds.
- Bion will become a step-down subsidiary post-completion, expected by month-end.
Price Impact
More from SAIPARENT